[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100486865":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":47,"centralContacts":51,"locations":60,"responsibleParty":81,"collaborators":42,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":42,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":42,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":107,"whyStopped":42,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Children's Mercy Hospital Kansas City","OTHER",[8,14,18,22,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine 4 mcg\u002Fkg","EXPERIMENTAL","Group One: Subjects will receive oral dexmedetomidine 4 mcg\u002Fkg 2 hours prior to MRI",[13],"Drug: Dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":17},"Dexmedetomidine 6 mcg\u002Fkg","Group Two: Subjects will receive oral dexmedetomidine 6 mcg\u002Fkg 2 hours prior to MRI",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Dexmedetomidine 8 mcg\u002Fkg","Group Three: Subjects will receive oral dexmedetomidine 8 mcg\u002Fkg 2 hours prior to MRI",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Dexmedetomidine 10 mcg\u002Fkg","Group Four: Subjects will receive oral dexmedetomidine 10 mcg\u002Fkg 2 hours prior to MRI",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Dexmedetomidine 12 mcg\u002Fkg","Group Five: Subjects will receive oral dexmedetomidine 12 mcg\u002Fkg 2 hours prior to MRI",[13],{"label":31,"type":32,"description":33,"interventionNames":34},"General anesthesia","ACTIVE_COMPARATOR","Control group: Subjects will receive general anesthesia for their MRI",[35],"Drug: General Anesthesia (control group)",[37,43],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","Dexmedetomidine","Participants will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI",[23,27,9,15,19],null,{"type":38,"name":44,"description":45,"armGroupLabels":46,"otherNames":42},"General Anesthesia (control group)","Participants will receive general anesthesia for their MRI",[31],[48],{"name":49,"affiliation":5,"role":50},"Soroush Merchant, MD, MS","PRINCIPAL_INVESTIGATOR",[52,56],{"name":49,"role":53,"phone":54,"phoneExt":42,"email":55},"CONTACT","816-3018595","smerchant@cmh.edu",{"name":57,"role":53,"phone":58,"phoneExt":42,"email":59},"Kelsye Howell, MSN, RN","816-760-5919","klhowell@cmh.edu",[61],{"facility":62,"status":42,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Children's Mercy Hospital","Kansas City","Missouri","64108","United States","US",{"type":69,"coordinates":70},"Point",[71,72],-94.57857,39.09973,{"lat":72,"lon":71},[75,77,78],{"name":49,"role":53,"phone":76,"phoneExt":42,"email":55},"816-301-8595",{"name":49,"role":50,"phone":42,"phoneExt":42,"email":42},{"name":79,"role":80,"phone":42,"phoneExt":42,"email":42},"Kristin Leland, MD","SUB_INVESTIGATOR",{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"SPONSOR_INVESTIGATOR","Soroush Merchant","Director of Medical Pain Service, Principal Investigator, Assistant Professor of Anesthesiology, MD, MS","100486865","phase-1-oral-dexmedetomidine-in-pediatric-mri-100486865",false,"NCT05619627","Oral Dexmedetomidine in Pediatric MRI","Utility of Oral Dexmedetomidine as the Sole Sedative Agent in Pediatric Population Undergoing MRI","Inclusion Criteria:\n\n1. Participants 3-6 years old, male and female, all races and ethnicities\n2. Requiring a clinically indicated MRI with general anesthesia\n\nExclusion Criteria:\n\n1. Refusal to take oral dexmedetomidine\n2. Known allergy to dexmedetomidine\n3. Inability to take dexmedetomidine at least 90 minutes prior to start of the MRI\n4. Medical contraindications to administration of dexmedetomidine including:\n\n   1. Unstable cardiac status including life threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction\n   2. Current use of digoxin\n   3. Moya Moya disease\n   4. New onset stroke\n5. American Society of Anesthesiologists (ASA) physical status classification \\> II\n6. Contraindications to administering sedation including:\n\n   1. Active and uncontrolled gastroesophageal reflux\n   2. Active and uncontrolled vomiting\n   3. Current or recent history of apnea\n   4. Active respiratory disease including pneumonia, bronchitis, respiratory syncytial virus infection, asthma exacerbation\n   5. Craniofacial anomalies\n7. Inability to have MRI scans\n8. Non-English speaking volunteers",true,"ALL","3 Years","6 Years",{"count":97,"type":98},18,"ESTIMATED","INTERVENTIONAL",[101],"PHASE1","The objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI.",[104],"Anesthesia",[106],"Oral dexmedetomidine","NOT_YET_RECRUITING","2026-06-24",{"date":110,"type":111},"2026-06-25","ACTUAL",{"date":113,"type":98},"2026-08-01",{"date":115,"type":98},"2027-12",{"name":83,"class":6},1]